Ajanta Pharma rises on receiving final approval from USFDA for Entacapone Tablets

04 Sep 2017 Evaluate

Ajanta Pharma is currently trading at Rs. 1204.95, up by 4.00 points or 0.33% from its previous closing of Rs. 1200.95 on the BSE.

The scrip opened at Rs. 1211.10 and has touched a high and low of Rs. 1215.65 and Rs. 1201.55 respectively. So far 1,465 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2150.00 on 28-Oct-2016 and a 52 week low of Rs. 1106.00 on 22-Aug-2017.

Last one week high and low of the scrip stood at Rs. 1249.00 and Rs. 1183.50 respectively. The current market cap of the company is Rs. 10,604.00 crore.

The promoters holding in the company stood at 73.78%, while Institutions and Non-Institutions held 13.81% and 12.41% respectively.

Ajanta Pharma has received final approval from US Food and Drug Administration (USFDA) for Entacapone Tablets. It is a bioequivalent generic version of Comtan Tablets. The company will be launching the product shortly in 200mg strength tablets.

Entacapone Tablets is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 35 Abbreviated New Drug Application (ANDA) of which it has final approvals for 20 ANDAs; tentative approvals for 2 ANDA; and 13 ANDAs are under review with USFDA.

Ajanta Pharma is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. Over 6,500 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 30+ countries.


Ajanta Pharma Share Price

2638.75 12.50 (0.48%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×